GlassScriptPhysician profile
Danyetta D Thomas
NPI 1316490709
$2,741.44
in general payments reported to CMS, 2019-2025
18 companies · $464 in 2025
The $464 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $107 · 2021: $244 · 2022: $578 · 2023: $355 · 2024: $558 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,377.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $907.19 | 2019-2025 | Rocklatan, Rhopressa, Simbrinza |
| Bausch & Lomb Americas INC. | $549.80 | 2022-2025 | Infuse, Biotrue One Day |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $292.36 | 2019-2021 | |
| Oyster Point Pharma, INC. | $252.35 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Glaukos Corporation | $132.56 | 2019 | |
| Shire North American Group INC | $121.24 | 2019 | |
| Aerie Pharmaceuticals, INC. | $76.52 | 2020-2021 | |
| Allergan, INC. | $68.50 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $65.28 | 2020-2022 | |
| Abbvie INC. | $57.04 | 2022 | |
| Apellis Pharmaceuticals, INC. | $51.57 | 2025 | |
| Tarsus Pharmaceuticals, INC. | $48.38 | 2024 | Xdemvy |
| Dompe US, INC. | $32.66 | 2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $22.63 | 2025 | Acthar |
| Horizon Therapeutics Plc | $16.63 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec, INC. | $16.12 | 2020 | |
| Coopervision INC. | $15.70 | 2024 | Myday Contact Lens |
| Harrow Eye, LLC | $14.91 | 2024 | Vevye |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danyetta Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.